ERIS Lifesciences Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 20, 2025, 10:32 pm

Quick Insight

ERIS Lifesciences Ltd, with a market cap of ₹22,816 Cr., is trading at a P/E of 58.9 and a P/BV of 4.42x, indicating a premium valuation within the pharmaceutical industry. The company boasts a healthy ROE and ROCE at 12.9% and 12.2% respectively, showcasing efficient capital utilization. With a strong OPM of 36%, ERIS demonstrates robust operational efficiency. However, the high borrowings of ₹2,478 Cr. raise concerns about leverage. The diversified shareholding pattern with significant promoter, FII, and DII holdings instills confidence. Overall, ERIS Lifesciences presents a mixed picture, with investors advised to monitor leverage levels closely for sustainable growth.

Competitors of ERIS Lifesciences Ltd

All Competitor Stocks of ERIS Lifesciences Ltd

Quarterly Result

Last Updated: August 20, 2025, 11:05 am

Below is a detailed analysis of the quarterly data for ERIS Lifesciences Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 773.00 Cr.. The value appears strong and on an upward trend. It has increased from 705.00 Cr. (Mar 2025) to 773.00 Cr., marking an increase of 68.00 Cr..
• For Expenses, as of Jun 2025, the value is 496.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 453.00 Cr. (Mar 2025) to 496.00 Cr., marking an increase of 43.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 277.00 Cr.. The value appears strong and on an upward trend. It has increased from 252.00 Cr. (Mar 2025) to 277.00 Cr., marking an increase of 25.00 Cr..
• For OPM %, as of Jun 2025, the value is 36.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 36.00%.
• For Other Income, as of Jun 2025, the value is 4.00 Cr.. The value appears to be declining and may need further review. It has decreased from 8.00 Cr. (Mar 2025) to 4.00 Cr., marking a decrease of 4.00 Cr..
• For Interest, as of Jun 2025, the value is 49.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 54.00 Cr. (Mar 2025) to 49.00 Cr., marking a decrease of 5.00 Cr..
• For Depreciation, as of Jun 2025, the value is 71.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 77.00 Cr. (Mar 2025) to 71.00 Cr., marking a decrease of 6.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 161.00 Cr.. The value appears strong and on an upward trend. It has increased from 129.00 Cr. (Mar 2025) to 161.00 Cr., marking an increase of 32.00 Cr..
• For Tax %, as of Jun 2025, the value is 22.00%. The value appears to be increasing, which may not be favorable. It has increased from 21.00% (Mar 2025) to 22.00%, marking an increase of 1.00%.
• For Net Profit, as of Jun 2025, the value is 125.00 Cr.. The value appears strong and on an upward trend. It has increased from 102.00 Cr. (Mar 2025) to 125.00 Cr., marking an increase of 23.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 8.66. The value appears strong and on an upward trend. It has increased from 6.89 (Mar 2025) to 8.66, marking an increase of 1.77.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: July 22, 2025, 3:53 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 3:17 pm

Below is a detailed analysis of the balance sheet data for ERIS Lifesciences Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 14.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 14.00 Cr..
• For Reserves, as of Mar 2025, the value is 2,841.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,573.00 Cr. (Mar 2024) to 2,841.00 Cr., marking an increase of 268.00 Cr..
• For Borrowings, as of Mar 2025, the value is 2,478.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 2,781.00 Cr. (Mar 2024) to 2,478.00 Cr., marking a decrease of 303.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 1,412.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,366.00 Cr. (Mar 2024) to 1,412.00 Cr., marking an increase of 46.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 6,744.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6,734.00 Cr. (Mar 2024) to 6,744.00 Cr., marking an increase of 10.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 5,306.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,319.00 Cr. (Mar 2024) to 5,306.00 Cr., marking an increase of 987.00 Cr..
• For CWIP, as of Mar 2025, the value is 67.00 Cr.. The value appears strong and on an upward trend. It has increased from 20.00 Cr. (Mar 2024) to 67.00 Cr., marking an increase of 47.00 Cr..
• For Investments, as of Mar 2025, the value is 67.00 Cr.. The value appears strong and on an upward trend. It has increased from 16.00 Cr. (Mar 2024) to 67.00 Cr., marking an increase of 51.00 Cr..
• For Other Assets, as of Mar 2025, the value is 1,304.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,379.00 Cr. (Mar 2024) to 1,304.00 Cr., marking a decrease of 1,075.00 Cr..
• For Total Assets, as of Mar 2025, the value is 6,744.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,734.00 Cr. (Mar 2024) to 6,744.00 Cr., marking an increase of 10.00 Cr..

Notably, the Reserves (2,841.00 Cr.) exceed the Borrowings (2,478.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for ERIS Lifesciences Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 24, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 1.00.
• For Basic EPS (Rs.), as of Mar 24, the value is 28.82. This value is within the healthy range. It has increased from 28.10 (Mar 23) to 28.82, marking an increase of 0.72.
• For Diluted EPS (Rs.), as of Mar 24, the value is 28.79. This value is within the healthy range. It has increased from 28.07 (Mar 23) to 28.79, marking an increase of 0.72.
• For Cash EPS (Rs.), as of Mar 24, the value is 42.61. This value is within the healthy range. It has increased from 36.12 (Mar 23) to 42.61, marking an increase of 6.49.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 190.11. It has increased from 163.30 (Mar 23) to 190.11, marking an increase of 26.81.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 190.11. It has increased from 163.30 (Mar 23) to 190.11, marking an increase of 26.81.
• For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 147.70. It has increased from 123.92 (Mar 23) to 147.70, marking an increase of 23.78.
• For PBDIT / Share (Rs.), as of Mar 24, the value is 51.36. This value is within the healthy range. It has increased from 40.29 (Mar 23) to 51.36, marking an increase of 11.07.
• For PBIT / Share (Rs.), as of Mar 24, the value is 37.94. This value is within the healthy range. It has increased from 31.68 (Mar 23) to 37.94, marking an increase of 6.26.
• For PBT / Share (Rs.), as of Mar 24, the value is 31.70. This value is within the healthy range. It has increased from 29.76 (Mar 23) to 31.70, marking an increase of 1.94.
• For Net Profit / Share (Rs.), as of Mar 24, the value is 29.19. This value is within the healthy range. It has increased from 27.51 (Mar 23) to 29.19, marking an increase of 1.68.
• For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 28.82. This value is within the healthy range. It has increased from 28.10 (Mar 23) to 28.82, marking an increase of 0.72.
• For PBDIT Margin (%), as of Mar 24, the value is 34.77. This value is within the healthy range. It has increased from 32.51 (Mar 23) to 34.77, marking an increase of 2.26.
• For PBIT Margin (%), as of Mar 24, the value is 25.68. This value exceeds the healthy maximum of 20. It has increased from 25.56 (Mar 23) to 25.68, marking an increase of 0.12.
• For PBT Margin (%), as of Mar 24, the value is 21.46. This value is within the healthy range. It has decreased from 24.01 (Mar 23) to 21.46, marking a decrease of 2.55.
• For Net Profit Margin (%), as of Mar 24, the value is 19.76. This value exceeds the healthy maximum of 10. It has decreased from 22.20 (Mar 23) to 19.76, marking a decrease of 2.44.
• For NP After MI And SOA Margin (%), as of Mar 24, the value is 19.50. This value is within the healthy range. It has decreased from 22.67 (Mar 23) to 19.50, marking a decrease of 3.17.
• For Return on Networth / Equity (%), as of Mar 24, the value is 15.15. This value is within the healthy range. It has decreased from 17.40 (Mar 23) to 15.15, marking a decrease of 2.25.
• For Return on Capital Employeed (%), as of Mar 24, the value is 11.42. This value is within the healthy range. It has decreased from 13.36 (Mar 23) to 11.42, marking a decrease of 1.94.
• For Return On Assets (%), as of Mar 24, the value is 5.56. This value is within the healthy range. It has decreased from 10.42 (Mar 23) to 5.56, marking a decrease of 4.86.
• For Long Term Debt / Equity (X), as of Mar 24, the value is 0.25. This value is within the healthy range. It has decreased from 0.29 (Mar 23) to 0.25, marking a decrease of 0.04.
• For Total Debt / Equity (X), as of Mar 24, the value is 1.06. This value exceeds the healthy maximum of 1. It has increased from 0.37 (Mar 23) to 1.06, marking an increase of 0.69.
• For Asset Turnover Ratio (%), as of Mar 24, the value is 0.37. It has decreased from 0.52 (Mar 23) to 0.37, marking a decrease of 0.15.
• For Current Ratio (X), as of Mar 24, the value is 0.90. This value is below the healthy minimum of 1.5. It has decreased from 1.73 (Mar 23) to 0.90, marking a decrease of 0.83.
• For Quick Ratio (X), as of Mar 24, the value is 0.83. This value is below the healthy minimum of 1. It has decreased from 1.43 (Mar 23) to 0.83, marking a decrease of 0.60.
• For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.11. This value is below the healthy minimum of 4. It has decreased from 1.26 (Mar 23) to 1.11, marking a decrease of 0.15.
• For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 26.15 (Mar 23) to 0.00, marking a decrease of 26.15.
• For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 20.01 (Mar 23) to 0.00, marking a decrease of 20.01.
• For Earning Retention Ratio (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 73.85 (Mar 23) to 0.00, marking a decrease of 73.85.
• For Cash Earning Retention Ratio (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 79.99 (Mar 23) to 0.00, marking a decrease of 79.99.
• For Interest Coverage Ratio (X), as of Mar 24, the value is 8.24. This value is within the healthy range. It has decreased from 20.94 (Mar 23) to 8.24, marking a decrease of 12.70.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 5.68. This value is within the healthy range. It has decreased from 15.30 (Mar 23) to 5.68, marking a decrease of 9.62.
• For Enterprise Value (Cr.), as of Mar 24, the value is 13,413.39. It has increased from 8,575.56 (Mar 23) to 13,413.39, marking an increase of 4,837.83.
• For EV / Net Operating Revenue (X), as of Mar 24, the value is 6.68. This value exceeds the healthy maximum of 3. It has increased from 5.09 (Mar 23) to 6.68, marking an increase of 1.59.
• For EV / EBITDA (X), as of Mar 24, the value is 19.20. This value exceeds the healthy maximum of 15. It has increased from 15.65 (Mar 23) to 19.20, marking an increase of 3.55.
• For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 5.70. This value exceeds the healthy maximum of 3. It has increased from 4.62 (Mar 23) to 5.70, marking an increase of 1.08.
• For Retention Ratios (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 73.84 (Mar 23) to 0.00, marking a decrease of 73.84.
• For Price / BV (X), as of Mar 24, the value is 4.42. This value exceeds the healthy maximum of 3. It has increased from 3.54 (Mar 23) to 4.42, marking an increase of 0.88.
• For Price / Net Operating Revenue (X), as of Mar 24, the value is 5.70. This value exceeds the healthy maximum of 3. It has increased from 4.62 (Mar 23) to 5.70, marking an increase of 1.08.
• For EarningsYield, as of Mar 24, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.04 (Mar 23) to 0.03, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness